Figure 5.
In vivo therapeutic efficacy of FL-L1-TubBH. MDA-MB231 tumor bearing mice were randomly divided into saline control, competition, and treated groups (n=5 for each group). Mice in saline control group were daily intravenously administered with saline whereas the mice in competition (FAP-Competition) group were co-injected with FL-L1-TubBH (40 nmoles) and FL (100-fold excess). Mice in treated groups were either administered every other day or daily with 40 nmoles of FL-L1-TubBH. Tumor volume (A) and weight (B) were monitored in mice in all the groups during the therapy. Each point in (A) represents mean tumor volume (mm3) ± SD, whereas each point in (B) represents mean weight (g) ± SD, *** represents p< 0.001 at day 7 and 17, ns indicates non-significant.